公开(公告)号：US20180214532A1

公开(公告)日：2018-08-02

申请号：US15883334

申请日：2018-01-30

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18

CPC classification number: A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6415 ,  A61K47/646 ,  A61P31/00 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20180000923A1

公开(公告)日：2018-01-04

申请号：US15543232

申请日：2016-02-16

Applicant: Pfizer Inc.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K39/12 ,  A61K47/22 ,  A61K47/64 ,  A61K47/26 ,  A61K47/02 ,  A61K39/00

Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US09802987B2

公开(公告)日：2017-10-31

申请号：US14773324

申请日：2014-03-05

Applicant: PFIZER INC.

Inventor： Deborah Ann Dilts ,  Annaliesa Sybil Anderson ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E Ruppen ,  Eugene Joseph Vidunas

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/38 ,  A61K39/385 ,  C07K14/22 ,  A61K39/095 ,  C07K14/315 ,  A61K39/09

CPC classification number: C07K14/22 ,  A61K39/092 ,  A61K39/095 ,  A61K2039/6037 ,  A61K2039/6068 ,  C07K14/3156 ,  C07K2319/00 ,  C07K2319/55

Abstract: In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.

公开(公告)号：US09561269B2

公开(公告)日：2017-02-07

申请号：US14604620

申请日：2015-01-23

Applicant: PFIZER INC.

Inventor： Gary Warren Zlotnick ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen ,  Annaliesa Sybil Anderson ,  John Erwin Farley ,  Liesel A. Bernfield

IPC: A61K39/095 ,  C07K16/22 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。